Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia

[1] Bargou R(2008)Tumor regression in cancer patients by very low doses of a T cell-engaging antibody Science 321 974-977

[2] Leo E(2012)Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL Blood 120 5185-5187

[3] Zugmaier G(2011)Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival J Clin Oncol 29 2493-2498

[4] Klinger M(2012)Impact of treatment reduction for childhood acute lymphoblastic leukemia on serum immunoglobulins and antibodies against vaccine-preventable diseases Pediatr Blood Cancer 58 701-707

[5] Goebeler M(2012)Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides PLoS One 7 e37626-277

[6] Knop S(2013)B-cell targeted therapeutics in clinical development Arthritis Res Ther 15 S4-111

[7] Topp MS(2010)Does rituximab aggravate pre-existing hypogammaglobulinaemia? J Clin Pathol 63 275-433

[8] Gokbuget N(2010)Rituximab Is associated with prolonged immunoglobulin deficiency in newly diagnosed patients with aggressive B-cell lymphoma receiving immunochemotherapy Blood 116 abstr 2881-508

[9] Zugmaier G(2013)Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections Clin Lymphoma Myeloma Leuk 13 106-1210

[10] Degenhard E(2008)Profound hypogammaglobulinemia 7 years after treatment for indolent lymphoma Cancer Invest 26 431-354

[1] Bargou R(2008)Tumor regression in cancer patients by very low doses of a T cell-engaging antibody Science 321 974-977

[2] Leo E(2012)Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL Blood 120 5185-5187

[3] Zugmaier G(2011)Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival J Clin Oncol 29 2493-2498

[4] Klinger M(2012)Impact of treatment reduction for childhood acute lymphoblastic leukemia on serum immunoglobulins and antibodies against vaccine-preventable diseases Pediatr Blood Cancer 58 701-707

[5] Goebeler M(2012)Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides PLoS One 7 e37626-277

[6] Knop S(2013)B-cell targeted therapeutics in clinical development Arthritis Res Ther 15 S4-111

[7] Topp MS(2010)Does rituximab aggravate pre-existing hypogammaglobulinaemia? J Clin Pathol 63 275-433

[8] Gokbuget N(2010)Rituximab Is associated with prolonged immunoglobulin deficiency in newly diagnosed patients with aggressive B-cell lymphoma receiving immunochemotherapy Blood 116 abstr 2881-508

[9] Zugmaier G(2013)Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections Clin Lymphoma Myeloma Leuk 13 106-1210

[10] Degenhard E(2008)Profound hypogammaglobulinemia 7 years after treatment for indolent lymphoma Cancer Invest 26 431-354